Vertex Pharma outperforms two quarters in a row

28 October 2022
money_big-1

Vertex Pharmaceuticals (Nasdaq: VRTX) has reported product revenues of $2.3 billion in the third quarter of 2020, an 18% increase on the same period of last year, while upping its revenue guidance for the year to around $8.85 billion.

For the second quarter in a row, the company handily outperformed expectations, with the FT consensus forecast set at $2.23 billion before the announcement.

Net income was $931 million, following Generally Accepted Accounting Principles (GAAP), a 9% jump, giving an earnings per share figure of $3.59.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical